ArticleThe American journal of case reports2026
Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is commonly treated with docetaxel/carboplatin/trastuzumab (TCbH). While anemia is a common complication, progression to pure red cell aplasia (PRCA) is extremely rare. This report presents the case of a 45-year-old woman with right breast ductal carcinoma (cT3N2M0, HER2-positive) who developed PRCA following neoadjuvant TCbH and was effectively treated with cyclosporine. CASE REPORT A 45-year-old woman with right breast invasive ductal carcinoma (cT3N2M0, HER2-positive) received neoadjuvant TCbH. After the sixth cycle, she developed progressive anemia refractory to erythropoietin, with hemoglobin (Hb) decreasing to 34.2 g/L. After transfusion, she underwent modified radical mastectomy with pathological complete response. Postoperatively, anemia worsened with marked reticulocytopenia (reticulocytes 3.8×10⁹/L; 0.2%). Bone marrow examination revealed markedly reduced erythroid precursors. Acquired PRCA was diagnosed after excluding iron deficiency, megaloblastic anemia, hemolytic anemia, hematologic malignancies, autoimmune disorders, aplastic anemia, thymoma, and infections. Oral cyclosporine (100 mg twice daily) induced complete hematologic remission at 7 weeks and was tapered over 2 years. During the adjuvant trastuzumab/pertuzumab (HP) treatment, Hb remained ≥110 g/L. A heterozygous germline BRCA1 mutation (c.788delG) was identified. At the 4.5-year follow-up, there is no recurrence of either breast cancer or anemia. CONCLUSIONS This case highlights PRCA as a severe complication of TCbH therapy. Reticulocytopenia with refractory anemia warrants timely bone marrow examination. In this patient, cyclosporine was effective; after anemia correction, HP was tolerated. The observed gBRCA1 mutation is a hypothesis-generating finding requiring further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.